
Inclusion criteria in retrospective cohort:
• Age ≥ 18 years old;
• Advanced or locally unresectable advanced (IIIB-IVB) non-small cell lung cancer patient;
• With EGFR sensitizing mutations (19Del or L858R);
• With concomitant BRAF Variations identified at initial diagnosis or disease progression.
Eligible patients, N=58
• Patients with EGFR mutation and de-novo BRAF alterations, n =6;
• Patients with EGFR mutation and BRAF alterations identified after progression of EGFR TKIs, n =52.
Excluded patients, N=23:
• Patients with Tier III or IV BRAF variants, n =16;
• Patients without treatment after identifying BRAF alterations, n =7.
Retrospective analysis of following treatment in patients with clinically significant BRAF variants, N=35.
Patients for following analysis, N=63:
• Analysis of characteristics;
• Clinical outcome (OS) analysis.
Inclusion criteria in prospective cohort:
• Age ≥ 18 years old;
• Advanced or locally unresectable advanced (ⅢB-ⅣB) non-small cell lung cancer patient;
• With EGFR sensitizing mutations (19Del or L858R);
• Identified with concomitant BRAF V600E after failure of osimertinib;
• ECOG PS ≤ 2;
• Informed consent provided.
Enrolled patients, N=5:
• Identified with concomitant BRAF V600E after failure of 1st line osimertinib, n =2;
• Identified with concomitant BRAF V600E after failure of 2nd line osimertinib, n =3;
osimertinib + BRAF inhibitors
Efficacy (PFS, ORR);
Safety.